$-0.23
(Market cap
$126,387 Mln
Recently Viewed
Clear AllMarket cap
$126,387 Mln
Revenue (TTM)
$24,778 Mln
P/E Ratio
34.6
P/B Ratio
2.4
Div. Yield
0.7 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$2,660 Mln
ROE
0.1 %
ROCE
5.3 %
Industry P/E
46.76
EV/EBITDA
19.7
Debt to Equity
0.3
Book Value
$--
EPS
$5.2
Face value
--
Shares outstanding
707,770,627
CFO
$52,782.40 Mln
EBITDA
$59,034.30 Mln
Net Profit
$38,691.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Danaher (DHR)
| -21.9 | -1.5 | -20.4 | -8.8 | -5.2 | -4.8 | 10.7 |
|
BSE Sensex
| -8.5 | 5.3 | -5.9 | -3.4 | 8.2 | 9.3 | 11.7 |
|
S&P 100
| 1.9 | 13.7 | 1.9 | 31.4 | 22.9 | 13.1 | 14.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Danaher (DHR)
| -0.3 | -0.8 | -1.7 | -19.3 | 48.6 | 45.3 | 49.6 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Danaher (DHR)
|
178.8 | 126,386.6 | 24,778.0 | 3,689.0 | 18.7 | 7.1 | 34.6 | 2.4 |
| 92.2 | 160,700.9 | 45,134.0 | 6,276.0 | 15.4 | 24.6 | 25.9 | 3.1 | |
| 56.5 | 97,626.9 | 20,615.0 | 3,553.0 | 10.0 | 30.4 | 27.5 | 4.0 | |
| 16.0 | 655.3 | 55.4 | 9.5 | 15.4 | 13.3 | 90.9 | 9.0 | |
| 450.9 | 170,784.4 | 10,582.1 | 2,979.1 | 22.4 | 17.2 | 58.5 | 9.7 | |
| 1.0 | 18.4 | 55.5 | -2.9 | -1.6 | -61.1 | -- | 269.8 | |
| 466.7 | 173,435.7 | 45,197.0 | 6,859.0 | 19.2 | 13.3 | 25.6 | 3.3 | |
| 66.0 | 213.9 | 37.5 | 10.9 | 27.3 | 9.1 | 19.5 | 1.8 | |
| 0.8 | 11.4 | 18.3 | -24.3 | -87.6 | -- | -- | 6.9 | |
| 294.0 | 21,629.5 | 3,220.4 | 542.7 | 15.3 | 18 | 41.3 | 7.3 |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics... segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia. Read more
Co-Founder & Chairman
Mr. Steven M. Rales
Co-Founder & Chairman
Mr. Steven M. Rales
Headquarters
Washington, DC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Danaher Corporation (DHR) is $178.76 (NYSE) as of 29-Apr-2026 11:44 EDT. Danaher Corporation (DHR) has given a return of -5.23% in the last 3 years.
The P/E ratio of Danaher Corporation (DHR) is 34.61 times as on 24-Apr-2026, a 26 discount to its peers’ median range of 46.76 times.
The P/B ratio of Danaher Corporation (DHR) is 2.39 times as on 24-Apr-2026, a 26 discount to its peers’ median range of 3.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
45.04
|
3.10
|
|
2024
|
43.40
|
3.42
|
|
2023
|
36.39
|
3.23
|
|
2022
|
27.45
|
3.95
|
|
2021
|
37.76
|
5.38
|
The 52-week high and low of Danaher Corporation (DHR) are Rs 242.75 and Rs 175.00 as of 29-Apr-2026.
Danaher Corporation (DHR) has a market capitalisation of $ 126,387 Mln as on 24-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Danaher Corporation (DHR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.